The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options

Value in Health

Volumn 20, Issue 2, 2017, Pages 266-272

  Mühlbacher, Axel C ^a   Sadler, Andrew ^a  

^a Hochschule Neubrandenburg   (Germany)

Author keywords

cost effectiveness analysis; efficiency frontier (EF); hepatitis C; multiple criteria decision analysis (MCDA); net monetary benefit (NMB); patient preferences; price acceptability curve (PAC)

Indexed keywords

BOCEPREVIR; DACLATASVIR; DASABUVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL EVALUATION; CLINICAL PRACTICE; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; EFFICIENCY FRONTIER; GERMANY; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MEDICAL DECISION MAKING; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; NET MONETARY BENEFIT; PATIENT PREFERENCE; PRICE ACCEPTABILITY CURVE; PRIORITY JOURNAL; TREATMENT DURATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE QUALITY; HEPATITIS C; PHARMACOECONOMICS; PROCEDURES; STATISTICAL MODEL;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; GERMANY; HEPATITIS C; HUMANS; LINEAR MODELS; PATIENT PREFERENCE; QUALITY OF HEALTH CARE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85012910790     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.12.015     Document Type: Article

References (34)

1. [1] Neumann, P.J., Cohen, J.T., Measuring the value of prescription drugs. N Engl J Med 373 (2015), 2595–2597.
2. [2] Institute for Quality and Efficiency in Health Care. General Methods. Version 4.2 of 22 April 2015. 2015. Available from: https://www.iqwig.de/download/IQWiG_General_Methods_Version_%204-2.pdf. [Accessed November 14, 2016].
3. [3] Drummond, M.F., Sculpher, M.J., Claxton, K., et al. Methods for the Economic Evaluation of Health Care Programmes. 2015, Oxford University Press, Oxford, UK.
4. [4] Drummond, M., Rutten, F., New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?. 2008, Office of Health Economics, OHE Briefing. London.
5. [5] Brouwer, W.B., Rutten, F.F., The efficiency frontier approach to economic evaluation: will it help German policy making?. Health Econ 19 (2010), 1128–1131.
6. [6] Caro, J.J., Nord, E., Siebert, U., et al. The efficiency frontier approach to economic evaluation of health‐care interventions. Health Econ 19 (2010), 1117–1127.
7. [7] Dintsios, C.M., Gerber, A., Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach. Health Econ 19 (2010), 1139–1141.
8. [8] Greiner, W., Kuhlmann, A., Schwarzbach, C., Ökonomische Beurteilung des Effizienzgrenzenkonzeptes [An economic evaluation of the IQWiG's efficient frontier] [German]. Gesundheitsökonomie Qualitätsmanagement 15 (2010), 241–250.
9. [9] Institute for Quality and Efficiency in Health Care. Documentation and evaluation of comments on the draft of the General Methods 4.2 [German]. 2015. Available from: https://www.iqwig.de/download/DWA_Methoden_4-2.pdf. [Accessed November 14, 2016].
10. [10] Institute for Quality and Efficiency in Health Care. Choice-based conjoint analysis—pilot project to identify, weight, and prioritize multiple attributes in the indication “hepatitis C.” 2014. Available from: https://www.iqwig.de/download/GA10-03_Executive-summary-of-working-paper-1.1_Conjoint-Analysis.pdf. [Accessed November 14, 2016].
11. [11] Gissel, C., Götz, G., Mahlich, J., et al. Cost-effectiveness of interferon-free therapy for hepatitis C in Germany—an application of the efficiency frontier approach. BMC Infect Dis, 15, 2015, 1.
12. [12] Siebert, U., Mühlberger, N., Conrads-Frank, A., et al. EE1 using IQWIG's efficiency frontier approach for the economic evaluation of hepatitis C treatment—a pilot and feasibility study commissioned by IQWiG. Value Health, 12, 2009, A225.
13. [13] Sroczynski, G., Long-term effectiveness and cost effectiveness of different antiviral treatments for chronic genotype-1 HCV infection in Germany including ombitasvir/paritaprevir/ritonavir and dasabuvir. 2016, Presented at: 16th Biennial SMDM-European Conference, London.
14. [14] Briggs, A., Sculpher, M., Claxton, K., Decision Modelling for Health Economic Evaluation. 2006, Oxford University Press, Oxford, UK.
15. [15] Stollenwerk, B., Lhachimi, S.K., Briggs, A., et al. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision‐makers. Health Econ 24 (2015), 481–490.
16. [16] Mühlbacher, A.C., Kaczynski, A., Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA. Appl Health Econ Health Policy 14 (2016), 29–40.
17. [17] Mühlbacher, A., Bethge, S., Kaczynski, A., et al. Objective criteria in the medicinal therapy for type II diabetes: an analysis of the patients’ perspective with analytic hierarchy process and best-worst scaling [German]. Das Gesundheitswes 78 (2016), 326–336.
18. [18] Marsh, K., Lanitis, T., Neasham, D., et al. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics 32 (2014), 345–365.
19. [19] Baltussen, R., Youngkong, S., Paolucci, F., et al. Multi-criteria decision analysis to prioritize health interventions: capitalizing on first experiences. Health Policy 96 (2010), 262–264.
20. [20] Figueira, J., Greco, S., Ehrgott, M., Multiple criteria decision analysis: state of the art surveys. 2005, Springer Science & Business Media, New York, NY.
21. [21] Thokala, P., Duenas, A., Multiple criteria decision analysis for health technology assessment. Value Health 15 (2012), 1172–1181.
22. [22] Marsh, K., IJzerman, M., Thokala, P., et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 19 (2016), 125–137.
23. [23] Briggs, A.H., Weinstein, M.C., Fenwick, E.A., et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–6. Med Decis Making 32 (2012), 722–732.
24. [24] Bacon, B.R., McHutchison, J.G., Into the light: strategies for battling hepatitis C. Am J Manag Care, 13, 2007, S319.
25. [25] Mühlberger, N., Schwarzer, R., Lettmeier, B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health, 9, 2009, 34.
26. [26] Gutteling, J., De Man, R., Van Der Plas, S., et al. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 23 (2006), 1629–1635.
27. [27] Gutteling, J., De Man, R., Busschbach, J., et al. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 65 (2007), 227–234.
28. [28] Robert-Koch-Institut (RKI). Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Hepatitis C im Jahr 2014. [The situation of major infectious diseases in Germany. Hepatitis in the year 2014] [German]. Epid Bull 2015;30:289-302.
29. [29] Serti, E., Chepa-Lotrea, X., Kim, Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
30. [30] Warpakowski, A., Hepatitis, C., new drugs stop the virus [German]. Dtsch Arztebl Int 111 (2014), 509–510.
31. [31] Sarrazin, C., Berg, T., Buggisch, P., et al. Aktuelle Empfehlung der DGVS zur Therapie der chronischen Hepatitis C [Current recommendation of the DGVS for the therapy of chronic hepatitis C] [German]. Z Gastroenterol 53 (2015), 320–334.
32. [32] Schwalm, A., Danner, M., Seidl, A., et al. Wo steht die Kosten-Nutzen-Bewertung des IQWiG: Abgleich mit einem internationalen Referenzszenario? [IQWiG's methods for the cost-benefit assessment: comparison with an international reference scenario] [German]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53 (2010), 615–622.
33. [33] Mühlbacher, A., Bethge, S., First and foremost battle the virus: eliciting patient preferences in antiviral therapy for hepatitis C using a discrete choice experiment. Value Health 19 (2016), 776–787.
34. [34] Institute for Quality and Efficiency in Health Care. Jahresbericht 2013 [Annual report 2013] [German]. 2013. Available from: https://www.iqwig.de/download/IQWiG_Jahresbericht_2013.pdf. [Accessed November 14, 2016].